IPSEN – Buy-back programme – Art 5 of MAR – Week 21 – 2026
Aggregated presentation by day and by market
| Purchases of own shares from May 18th to May 22nd 2026 | ||||||
| Name of the Issuer | Identity code of the Issuer | Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 18/05/2026 | FR0010259150 | 6 250 | 156,0471 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 18/05/2026 | FR0010259150 | 750 | 153,2719 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 19/05/2026 | FR0010259150 | 5 000 | 157,2830 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/05/2026 | FR0010259150 | 612 | 157,3580 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 21/05/2026 | FR0010259150 | 4 000 | 160,1990 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 22/05/2026 | FR0010259150 | 3 000 | 161,0347 | XPAR |
| TOTAL | 19 612 | 157,9067 | ||||
Attachment

IPSEN – Buy-back programme – Art 5 of MAR – Week 21 – 2026
Aggregated presentation by day and by market
| Purchases of own shares from May 18th to May 22nd 2026 | ||||||
| Name of the Issuer | Identity code of the Issuer | Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 18/05/2026 | FR0010259150 | 6 250 | 156,0471 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 18/05/2026 | FR0010259150 | 750 | 153,2719 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 19/05/2026 | FR0010259150 | 5 000 | 157,2830 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/05/2026 | FR0010259150 | 612 | 157,3580 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 21/05/2026 | FR0010259150 | 4 000 | 160,1990 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 22/05/2026 | FR0010259150 | 3 000 | 161,0347 | XPAR |
| TOTAL | 19 612 | 157,9067 | ||||
Attachment

Related stories
Retrouver la lumière : le parcours de Rajminder Malhi
Quand les acides biliaires prennent une dimension plus large : comment la biologie de la cholestase transforme la recherche sur les maladies hépatiques rares
Tester l’hypothèse : un pilote ciblé sur l’IA dans le domaine de la santé
Related Press Releases
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen provides update on Phase III BOLD trial in biliary...
Ipsen – Corrective statement amending the monthly disclosure of the...
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset...
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen – June 2026 – Monthly information relative to the...
Ipsen – Half year statement – 2026 06 30
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...